Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy

被引:34
|
作者
Patil, Pallavi A. [1 ]
Zhang, Xuchen [1 ]
机构
[1] Yale Univ, Dept Pathol, Sch Med, 310 Cedar St,POB 208023, New Haven, CT 06520 USA
关键词
NIVOLUMAB-RELATED CHOLANGITIS; LYMPHOCYTIC COLITIS; ADVERSE EVENTS; IPILIMUMAB; IMMUNOTHERAPY; FEATURES; HEPATITIS; CANCER; PEMBROLIZUMAB; ASSOCIATION;
D O I
10.5858/arpa.2020-0070-RA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Immune checkpoint inhibitors (CPIs), including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors, are being increasingly used for treating many advanced malignancies. However, CPI therapy is also associated with gastrointestinal and hepatobiliary adverse effects. Objectives.-To review the adverse effects of CPI therapy on the gastrointestinal tract and hepatobiliary system. To describe histopathologic patterns and discuss differential diagnostic considerations in the diagnosis of CPI injuries. Data Sources.-Published peer-reviewed literature in the English language and personal experience in the diagnosis of CPI injuries. Conclusions.- The pathologic manifestations of CPI therapy-induced gastrointestinal and hepatobiliary injury are broad. The patterns of esophageal CPI injury include lymphocytic inflammation and ulcerative esophagitis, while those of gastric injury include chronic active gastritis, lymphocytic gastritis, focal enhancing gastritis, and periglandular inflammation. The duodenal injury may present as duodenitis with villous blunting and granulomas. We also noticed active colitis, microscopic colitis, chronic active colitis, increased apoptosis, ischemic colitis, and nonspecific inflammatory reactive changes in colonic injuries. The reported histologic features of hepatobiliary injuries are panlobular hepatitis, centrilobular necrosis, portal inflammation with bile duct injury, steatosis, nodular regenerative hyperplasia, and secondary sclerosing cholangitis. In summary, we discuss the pathologic features and differential diagnosis of CPI therapy-induced gastrointestinal and hepatobiliary injury. Recognition of CPI injury is important to determine the proper management that often includes cessation of CPI therapy, and administration of steroids or other immunosuppressive agents, based on severity of injury.
引用
收藏
页码:571 / 582
页数:12
相关论文
共 50 条
  • [41] Toxicity in the era of immune checkpoint inhibitor therapy
    Keam, Synat
    Turner, Naimah
    Kugeratski, Fernanda G.
    Rico, Rene
    Colunga-Minutti, Jocelynn
    Poojary, Rayansh
    Alekseev, Sayan
    Patel, Anisha B.
    Li, Yuanteng Jeff
    Sheshadri, Ajay
    Loghin, Monica E.
    Woodman, Karin
    Aaroe, Ashley E.
    Hamidi, Sarah
    Iyer, Priyanka Chandrasekhar
    Palaskas, Nicolas L.
    Wang, Yinghong
    Nurieva, Roza
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [42] ACUTE KIDNEY INJURY ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY: REPORT OF 4 CASES
    Sardeli, Angeliki
    Petrou, Dimitra
    Kalogeropoulos, Petros
    Nikolopoulos, Petros
    Liapis, George
    Lionaki, Sophia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I333 - I333
  • [43] Sex differences in immune checkpoint receptor expression in patients with upper gastrointestinal malignancies: potential implications for patient response to immune checkpoint inhibitor therapy
    Kilgallon, Aoife
    Menon, Meghana
    Murphy, Kirstan
    Moran, Brendan
    Reynolds, John V.
    Lysaght, Joanne
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 756 - 756
  • [44] Immune Checkpoint Inhibitor-Induced Liver Injury
    Gudd, Cathrin L. C.
    Sheth, Roosey
    Thursz, Mark R.
    Triantafyllou, Evangelos
    Possamai, Lucia A.
    SEMINARS IN LIVER DISEASE, 2023, 43 (04) : 402 - 417
  • [45] Immune checkpoint inhibitor-associated myocarditis: manifestations arms mechanisms
    Moslehi, Javid
    Lichtman, Andrew H.
    Sharpe, Arlene H.
    Galluzzi, Lorenzo
    Kitsis, Richard N.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (05):
  • [46] CHECKPOINT CONFUSION, ASEPTIC ENCEPHALITIS AFTER IMMUNE CHECKPOINT INHIBITOR THERAPY
    Roperia, Varun
    CHEST, 2024, 166 (04) : 2342A - 2345A
  • [47] Immune Checkpoint Inhibitors and Their Impact on Thoughts, Feelings, and Behavior: Cognitive and Psychiatric Manifestations of Immune Checkpoint Therapy
    Ahuja, Jai
    Varma, Kushagra
    INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2024,
  • [48] Therapy: Rheumatic disease after immune checkpoint inhibitor therapy
    Ummarino D.
    Nature Reviews Rheumatology, 2017, 13 (8) : 450 - 450
  • [49] Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy
    Zhang, Qiongyan
    Chen, Lingli
    Guo, Xinxin
    Shen, Licheng
    Huang, Yufeng
    Chen, Yi
    Zhang, Ningping
    Ge, Ningling
    Gao, Hong
    Zhang, Wen
    Hou, Yingyong
    Ji, Yuan
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 68
  • [50] Early Experience of Combining Immune Checkpoint Inhibitor and Radiotherapy in Heavily Pretreated Hepatobiliary Cancer
    Kim, Y. T.
    Lee, B. M.
    Seong, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E175 - E176